Literature DB >> 31656402

Effectiveness of emergency physician determinations of the need for thrombolytic therapy in acute stroke.

Andrew L Juergens1, Jacob Barney1, Maneesha Julakanti2, Leigh Allen3, Courtney Shaver4.   

Abstract

An increased emphasis on stroke care has led to a proliferation of specialized stroke teams despite relatively few trials demonstrating their efficacy. Our academic stroke center incorporated a unique setup allowing for the comparison between stroke teams and emergency physicians. During weekday working hours, a stroke team would respond to the emergency department for stroke activations. During all other times, the emergency physician caring for the patient would make all treatment decisions. We sought to determine whether there was any difference in treatment and outcomes between these two groups. We conducted a retrospective review of all stroke activations from January 2015 to June 2016 and compared the thrombolytic administration rates, modified Rankin Scale (mRS) at discharge, and change in National Institutes of Health Stroke Scale (NIHSS). A total of 415 stroke activations were identified. Of those, 69 of 262 patients (26.3%) seen by emergency physicians and 60 of 153 patients (39.2%) seen by neurologists received thrombolysis (P = 0.006). No significant difference was found in the discharge mRS or change in NIHSS between the two groups. Emergency physicians administered significantly less thrombolytics than did neurologists. No significant difference was observed in outcomes, including mRS and admission-to-discharge change in NIHSS.
Copyright © 2019 Baylor University Medical Center.

Entities:  

Keywords:  Brain infarction; emergency medicine; patient care team

Year:  2019        PMID: 31656402      PMCID: PMC6793957          DOI: 10.1080/08998280.2019.1632779

Source DB:  PubMed          Journal:  Proc (Bayl Univ Med Cent)        ISSN: 0899-8280


  16 in total

1.  Timeliness of tissue-type plasminogen activator therapy in acute ischemic stroke: patient characteristics, hospital factors, and outcomes associated with door-to-needle times within 60 minutes.

Authors:  Gregg C Fonarow; Eric E Smith; Jeffrey L Saver; Mathew J Reeves; Deepak L Bhatt; Maria V Grau-Sepulveda; DaiWai M Olson; Adrian F Hernandez; Eric D Peterson; Lee H Schwamm
Journal:  Circulation       Date:  2011-02-10       Impact factor: 29.690

2.  Do efforts to decrease door-to-needle time risk increasing stroke mimic treatment rates?

Authors:  Ava L Liberman; Eric M Liotta; Fan Z Caprio; Ilana Ruff; Matthew B Maas; Richard A Bernstein; Rahul Khare; Deborah Bergman; Shyam Prabhakaran
Journal:  Neurol Clin Pract       Date:  2015-06

3.  Setting Up a Stroke Team Algorithm and Conducting Simulation-based Training in the Emergency Department - A Practical Guide.

Authors:  Damla Tahtali; Ferdinand Bohmann; Peter Rostek; Marlies Wagner; Helmuth Steinmetz; Waltraud Pfeilschifter
Journal:  J Vis Exp       Date:  2017-01-15       Impact factor: 1.355

4.  A Network-Wide Stroke Team Program Reduces Time to Treatment for Endovascular Stroke Therapy in a Regional Stroke-Network.

Authors:  Ferdinand O Bohmann; Damla Tahtali; Natalia Kurka; Marlies Wagner; Se-Jong You; Richard du Mesnil de Rochemont; Joachim Berkefeld; Ann-Kathrin Hartmetz; Andrea Kuhlmann; Matthias W Lorenz; Ansgar Schütz; Bodo Kress; Christian Henke; Stephanie Tritt; Uta Meyding-Lamadé; Helmuth Steinmetz; Waltraud Pfeilschifter
Journal:  Cerebrovasc Dis       Date:  2018-03-27       Impact factor: 2.762

5.  Trends in yield of a code stroke program for enhancing thrombolysis.

Authors:  Ahro Kim; Ji Sung Lee; Ji Eun Kim; Young Min Paek; Kyuyoon Chung; Ji-Hyeon Park; Yong-Jin Cho; Keun-Sik Hong
Journal:  J Clin Neurosci       Date:  2014-10-01       Impact factor: 1.961

6.  Implementation of stroke teams and simulation training shortened process times in a regional stroke network-A network-wide prospective trial.

Authors:  Damla Tahtali; Ferdinand Bohmann; Natalia Kurka; Peter Rostek; Anelia Todorova-Rudolph; Martin Buchkremer; Mario Abruscato; Ann-Kathrin Hartmetz; Andrea Kuhlmann; Christian Henke; André Stegemann; Sanjay Menon; Björn Misselwitz; Anke Reihs; Stefan Weidauer; Sven Thonke; Uta Meyding-Lamadé; Oliver Singer; Helmuth Steinmetz; Waltraud Pfeilschifter
Journal:  PLoS One       Date:  2017-12-05       Impact factor: 3.240

7.  Risk of intracerebral haemorrhage with alteplase after acute ischaemic stroke: a secondary analysis of an individual patient data meta-analysis.

Authors:  William N Whiteley; Jonathan Emberson; Kennedy R Lees; Lisa Blackwell; Gregory Albers; Erich Bluhmki; Thomas Brott; Geoff Cohen; Stephen Davis; Geoffrey Donnan; James Grotta; George Howard; Markku Kaste; Masatoshi Koga; Rüdiger von Kummer; Maarten G Lansberg; Richard I Lindley; Patrick Lyden; Jean Marc Olivot; Mark Parsons; Danilo Toni; Kazunori Toyoda; Nils Wahlgren; Joanna Wardlaw; Gregory J Del Zoppo; Peter Sandercock; Werner Hacke; Colin Baigent
Journal:  Lancet Neurol       Date:  2016-06-08       Impact factor: 44.182

Review 8.  Thrombolysis for acute ischaemic stroke.

Authors:  Joanna M Wardlaw; Veronica Murray; Eivind Berge; Gregory J del Zoppo
Journal:  Cochrane Database Syst Rev       Date:  2014-07-29

Review 9.  Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials.

Authors:  Jonathan Emberson; Kennedy R Lees; Patrick Lyden; Lisa Blackwell; Gregory Albers; Erich Bluhmki; Thomas Brott; Geoff Cohen; Stephen Davis; Geoffrey Donnan; James Grotta; George Howard; Markku Kaste; Masatoshi Koga; Ruediger von Kummer; Maarten Lansberg; Richard I Lindley; Gordon Murray; Jean Marc Olivot; Mark Parsons; Barbara Tilley; Danilo Toni; Kazunori Toyoda; Nils Wahlgren; Joanna Wardlaw; William Whiteley; Gregory J del Zoppo; Colin Baigent; Peter Sandercock; Werner Hacke
Journal:  Lancet       Date:  2014-08-05       Impact factor: 79.321

10.  Citation bias favoring positive clinical trials of thrombolytics for acute ischemic stroke: a cross-sectional analysis.

Authors:  Benjamin S Misemer; Timothy F Platts-Mills; Christopher W Jones
Journal:  Trials       Date:  2016-09-28       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.